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Molecular investigation of 
coexistent chronic myeloid 
leukaemia and peripheral T-cell 
lymphoma – a case report
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Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm underlain by the formation of  
BCR-ABL1 – an aberrant tyrosine kinase – in the leukaemic blasts. Long-term survival rates in CML 
prior to the advent of tyrosine kinase inhibitors (TKIs) were dismal, albeit the incidence of secondary 
malignancies was higher than that of age-matched population. Current figures confirm the safety 
of TKIs with conflicting data concerning the increased risk of secondary tumours. We postulate that 
care has to be taken when distinguishing between coexisting, secondary-to-treatment and second 
in sequence, but independent tumourigenic events, in order to achieve an unbiased picture of the 
adverse effects of novel treatments. To illustrate this point, we present a case of a patient in which 
CML and peripheral T-cell lymphoma (PTCL) coexisted, although the clinical presentation of the latter 
followed the achievement of major molecular response of CML to TKIs.
 
Chronic myeloid leukaemia (CML) is clonal stem cell disorder driven by the BCR-ABL1 fusion gene 
resulting from a reciprocal translocation between chromosomes 9 and 22 (the Philadelphia (Ph) chromo-
some) that gives rise to an aberrant chimeric tyrosine kinase (TK) (reviewed in1). Most patients are diag-
nosed in the chronic phase (CP) characterised by hepatosplenomegaly, thrombocytosis, and increased 
white blood count (WBC) made up of mature granulocytes and their precursors (reviewed in1). Until 
relatively recently, the natural disease history evolved from the CP – usually lasting several years – to 
the ultimately fatal accelerated (AP) and blast (BP) phases. The development of the TK inhibitors (TKIs) 
has allowed for the achievement of major molecular response (MMR) and long-term disease control2. 
A small percentage (< 5%) of cases treated with TKIs for CML develops second cancer3. These include 
mostly skin comprising melanoma, prostate and gut tumours3,4. Second haematological tumours in these 
series of patients are rare albeit exist3,4. On the other hand, cases of concurrent CML plus another haema-
tological disorder (or even two5), such as myeloma or B-cell non-Hodgkin lymphoma (NHL), have been 
reported6,7 (and references therein). An exact distinction between a secondary and coexisting malignancy 
may prove problematic. Here we report a case of CML diagnosed in CP, in which the treatment with 
imatinib led to the disclosure of lymphocytosis, later identified as peripheral T-cell lymphoma (PTCL). 
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Molecular analyses showed the presence of the lymphoma cells in the diagnostic sample taken at the time 
of CML onset arguing for the coexistence of the two disorders.
Case Report
A 55-year-old man presented with leucocytosis (Hb 12.2 g/dL, Plt 292 × 109/L, WBC 75.5 × 109/L) and 
splenomegaly. A peripheral blood (PB) and bone marrow (BM) morphological examination were con-
sistent with the chronic phase of a myeloproliferative disorder. Conventional cytogenetic analysis of BM 
revealed a normal male karyotype with the presence of Ph chromosome in 21/21 metaphases. Quantitative 
reverse transcription polymerase chain reaction (qRT-PCR) using the ipsogen BCR-ABL1 Mbcr IS-MMR 
Kit (Qiagen, Hilden, Germany) detected existence of the p210 fusion transcript and the BCR-ABL1/ABL1 
ratio of 106.25% was determined. The diagnosis of low-risk (according to Sokal score) Ph+ CML in 
chronic phase (CML-CP) was thus made. After an initial cytoreduction using hydroxyurea for two weeks, 
standard dose imatinib treatment was initiated. Within 3 months of treatment, complete haematologi-
cal response anti-CML (CHR, Fig. 1A) and > 2log reduction of BCR-ABL1/ABL1 ratio (down to 0.73%) 
were achieved albeit persistent lymphocytosis occurred (PB lymphocyte count > 5.0 × 109/L, Fig. 1A). At 
10 months, lymphocytosis worsened despite the achievement of major molecular response (MMR; PB 
BCR-ABL1/ABL1 ratio 0.02%; Fig. 1A) and further investigations revealed clonal expansion of karyotypi-
cally (Fig. 1B) and phenotypically (Fig. 1C) aberrant T-cells in PB and, later, in BM. Furthermore, mono-
clonal gamma-T-cell receptor gene rearrangement was detected in BM-derived DNA by PCR and low-level 
(10%) CD34-negative T-cell infiltration was found in BM whilst total body CT scan showed generalised 
lymphadenopathy. These findings together with histological examination of lymph node biopsy prompted 
the diagnosis of PTCL, not otherwise specified (NOS), and appropriate treatment commenced. First 
(CHOP-like chemotherapy) and second (IGEV poly-chemotherapy) line therapies failed. Instead, complete 
haematological and cytogenetic response of lymphoma was reached following the third line approach i.e. 
immunochemotherapy (Campath monoclonal antibody plus gemcitabine). During lymphoma treatment, 
imatinib was put on hold due to therapy/lymphoma-related myelosuppression without a negative effect 
on MMR of the CML. Considering the availability of a familial donor and refractory PTCL, the patient 
underwent a PB stem cell transplant (PBSCT). Donor granulocyte engraftment and complete remission 
of both haematological diseases lasted for six months after the procedure. Thereafter, progressive engraft-
ment failure and the expansion of recipient haematopoiesis followed. The patient died at 11 months from 
PBSCT due to respiratory failure. Figure 1A summarises the clinical and treatment history of the patient.
Results
The BCR-ABL1 protein found in the patient was of the p210 type and the breakpoints were ascertained 
by PCR with primers BCR-b1-A and ABL-a3-B (all primer sequences are given in Table 1). The finding of 
an amplicon of 417bp identified the transcript as b3-a2. Conventional cytogenetic analysis, performed at 
presentation of the second malignancy, has disclosed the presence of a t(X;14)(q28;q11) in the lymphoma 
cells. This translocation has been previously described to result in the breakage of the BRCC3 gene and its 
fusion to the T-cell receptor alpha or delta (TCRA/D) locus on chromosome 14. We confirmed by PCR 
amplification and subsequent sequencing the involvement of the two loci. Next, in order to track the ori-
gins of the lymphoma, we designed primers (primers X;14_F1, X;14_R1) mapping up and down-stream 
of the fusion junction and applied them to cDNA retrotranscribed from mRNA sample extracted at the 
time of CML diagnosis. The end point-qualitative PCR experiments showed that the transcript deriving 
from the t(X;14) translocation fusion was present at the time of the first diagnosis (Fig. 2A, top panel). 
In parallel, we have looked for the BCR-ABL1 fusion in mRNA deriving from PB sample taken at the 
time of PTLC diagnosis and found BCR-ABL1 transcript in it (Fig. 2A, bottom panel) although at very 
low levels (primers BCR-b1-A and ABL-a3-B). The specificity of the faint band seen in the lane corre-
sponding to the PTCL diagnostic sample was confirmed in a nested PCR protocol (primers BCR-b2-C 
and ABL-a3-D). Thus, we quantified the transcripts of the two translocations by qRT-PCR using two 
primer pairs for each fusion (qBCR_F1, qABL_R1, qBCR_F2, qABL_R2, X;14_F1, X;14_R1, X;14_F2, 
X;14_R2) and the SybrGreen methodology on both diagnostic samples and found that the expres-
sion level of the t(X;14) product in the diagnostic CML sample was about 4% of the expression of the 
BCR-ABL1 fusion transcript in the same sample, whereas the expression of BCR-ABL1 in the diagnostic 
PTCL sample was more than 10 times less (Fig. 2B). Next, we enumerated the reciprocal tumour burden 
in the two diagnostic samples by performing interphase FISH on archival methanol/acetic acid-fixed bone 
marrow samples taken at the times of CML and PTCL diagnoses. We used commercial probes designed 
to detect the presence of BCR/ABL fusion or TCRA/D locus breakage on the chromosome 14 caused by 
the t(X;14) formation. The experiments with the Vysis LSI BCR/ABL DC/DF probe (Abbott Molecular 
Inc., Des Plaines, IL, USA) disclosed the presence of an atypical hybridisation pattern consisting of one 
fusion signal, two green and one red signal (Fig.  3a). Such pattern has previously been reported and 
corresponds to a microdeletion of the reciprocal ABL locus. Cells with BCR/ABL fusion signal consti-
tuted 82% of the nuclei scored in the diagnostic CML sample. Not a single BCR/ABL+ cell was seen 
in the diagnostic PCTL sample when scoring a 1000 cells. FISH experiments with the use of TCRA/D 
Break-apart probe (Cytocell, Cambridge, UK) showed that the diagnostic CML sample contained about 
4.6% (48/1028) of cells with the rearrangement in the TCRA/D locus (Fig.  3B), whilst at the time of 
PTCL diagnosis the percentage of such cells increased to 83%. We next applied the two probes together 
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Figure 1. (A) Clinical and treatment history of the patient. Hb – haemoglobin, PLT – platelets, WBC 
– white blood count, HU – hydroxyurea, CHOP - cyclophosmamide, hydroxydaunorubicin, oncovin 
(vincristine), prednisone, IGEV - ifosfamide, gemcitabine, vinorelbine, CHR (complete haematological 
response), PCgR – partial cytogenetic response, CCgR – complete cytogenetic response, MMR – major 
molecular response, SD – stable disease, PTCL NOS – peripheral T-cell lymphoma not otherwise specified. 
(B) A representative karyotype obtained by culturing peripheral blood T-cells and staining the resulting 
metaphases with the standard Q-banding technique. (C) Immunophenotype of the peripheral blood T-cells 
showing the presence of an aberrant clone.
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Primer name: Sequence (5′–>3′) Use
BCR-b1_A* GAAGTGTTTCAGAAGCTTCTCC End-point qualitative PCR
ABL-a3_B* GTTTGGGCTTCACACCATTCC
BCR-b2_C* CAGATGCTGACCAACTCGTGT Nested end-point qualitative PCR
ABL-a3-D* TTCCCCATTGTGATTATAGCCTA








Table 1.  Primers used for the study. *Primer sequence published in20.
Figure 2. Molecular study of the presence of BCR-ABL1 and t(X;14)-derived fusion transcripts in 
diagnostic samples corresponding to the two malignancies. (A) End-point qualitative PCR for the 
translocation product fusions using primers that map up and down stream of the breakpoints. For t(9;22) 
also nested PCR was performed. Sample legend: 1 – CML (diagnostic PB sample), 2 – T-NHL (diagnostic 
PB sample), 3 – H2O, * – 1st round PCR product diluted 1:100 before being used as template in nested 
PCR. The bands visible in the no-template control lanes are due to primer dimer. (B) Quantitative PCR for 
the fusion gene transcripts. A graph of relative expression and tables of average Cts are shown. The relative 
quantity was calculated considering the amount of BCR-ABL1, normalised to ubiquitin, as 100% in the 
diagnostic CML sample and t(X;14) translocation product 100% in the diagnostic lymphoma sample.
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taking advantage of the fact that there is a substantial difference in size between the two, with probes 
for BCR and ABL being four times bigger than the TCRA/D Break-apart ones (600 kb vs ~150 kb). Cells 
with BCR/ABL fusion and no TCRA/D rearrangement as well as cells with TCRA/D split and no BCR/
ABL fusion were identified in percentages equal to the ones seen for single-probe experiments. No cells 
with both abnormalities were encountered in the diagnostic CML sample (Fig. 3C).
Discussion
Second malignancies diagnosed in patients previously treated for cancer can represent de novo unrelated 
oncogenic processes or be related/induced by the treatment received. Advances in diagnostics as well as 
in curative and supportive therapy have increased the number of long-term cancer survivors that may be 
prone to the development of secondary tumours arising from normal tissue exposure to the damaging 
effects of ionizing radiation or genotoxic stress of chemotherapy8–11. Recently, reports are emerging of 
additional secondary premalignant and malignant events, including RAS-mutant leukaemia, in mela-
noma patients on BRAF-inhibitors12. In particular, the patterns of incidence and latency of secondary 
lymphomas are distinct from that of myeloid malignancies and solid cancers. Indeed, the risk of sec-
ondary lymphomas increases after the first 5 years of completion of chemotherapy or radiotherapy and 
persists for more than three decades13. The lymphocytosis observed in our patient as soon as 3 months 
since the beginning of treatment with imatinib did not follow this pattern and prompted us to study 
the temporal relationship between the two malignancies. Interestingly, the occurrence of mono-/oligo-
clonal T-cell- or NK-cell- large granular lymphocyte lymphocytosis has been reported in a proportion of 
patients treated with dasatinib and to a lesser extent in those treated with imatinib14.
In order to answer the question of whether the two diseases manifested in the case presented here 
were genetically related or a coincidence, we took advantage of the presence of disease-specific translo-
cations as clonal markers and looked for the presence of sequences derived from the respective fusions 
in the reciprocal diagnostic samples. The end point-qualitative PCR experiments showed that the tran-
script deriving from the t(X;14)(q28;q11) translocation fusion was already present at the time of the first 
diagnosis suggesting that a small clone of lymphoma cells existed 10 months before the finding of an 
overt lymphoma or that a small subclone of BCR-ABL1 bearing cells existed in which t(X;14) was also 
present. However, FISH experiments confirmed that there were no cells in which the two translocations 
co-existed, i.e. PTCL cells are BCR/ABL negative. This is inconsistent with the theory of a subclone of 
CML evolving into PTCL as one would expect that such clonal evolution resulted in a cell that contin-
ued to bear t(9;22) and express BCR-ABL1. There is a slight discrepancy between the results of qPCR 
and FISH data when it comes to the evaluation of the CML burden at the time of PTCL diagnosis. The 
explanation for it includes several issues – the transcript levels/cell and the efficiency of PCR for the two 
primer pairs may be different in the two clones, the Cts were high and therefore outside of the range of 
accurate quantification. Nonetheless, there is no doubt as to the presence of residual BCR-ABL1 tran-
script at the time of PTCL diagnosis, as diagnostic and nested protocols showed its presence.
The novelty of the case described here lies also in the finding of the t(X;14)(q28;q11) translocation 
in PTCL. This translocation, together with the more frequent inversion of the chromosome 14, has been 
previously described in T-cell prolymphocytic leukaemia15, admittedly, a disease from within the same 
spectrum of lymphoproliferations. PTCL NOS constitutes a rare and aggressive tumour whose molecular 
pathogenesis is still challenging16, albeit shedding light on the tumourigenesis of this disease entity is 
beyond the scope of this report.
Although secondary tumours have been described after imatinib therapy, the analyses of their fre-
quency with respect to the age-adjusted general population yielded conflicting results3,4,17–19. Differences 
in cohort size, follow-up time and the interpretation of the term “secondary cancer” may have been 
responsible for this difference. Moreover, many of the above mentioned studies analysed historical data 
from cancer registries selecting patients treated with diverse modalities over variable periods of time. 
Clearly, working with historical data, especially if old, gives no opportunity of reviewing and confirming 
the diagnosis, anamnesis and so on. In the most recent article on the incidence of second malignancies 
following treatment with TKIs, Gunnarsson et al.19 reported an increased risk of a second cancer for the 
population of CML sufferers, indicating that such risk may more likely be related to the CML itself and 
not to the therapy with imatinib or other inhibitors. Without doubt, TKIs have dramatically changed the 
prognosis of patients with CML and are considered safe, well tolerated and non-mutagenic2. Our study 
suggests that in some cases the second malignancy is not secondary to TKIs treatment but instead was 
present at the time of diagnosis of CML. In such cases, the eradication of CML with the use of TKIs may 
create an opportunity for the lymphoma to develop overtly. We underline the importance of investigating 
the possibility that the second cancer in the context of a previous CML diagnosis was pre- or co-existent.
Methods
We obtained informed consent from the patient prior to sample collection. The ipsogen BCR-ABL1 
Mbcr IS-MMR Kit (Qiagen, Hilden, Germany) was used according to manufacturer’s instructions. 
Immunophenotypic/cytogenetic analyses of CML and PTCL were performed following standard diag-
nostic procedures and were carried out in accordance with the guidelines approved by Ethics Committee 
of the Istituto Europeo di Oncologia, Milan, Italy. Primers listed in Table  1 were used for molecular 
characterisation of breakpoints and specific transcript detection. Standard PCR reactions were performed 
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Figure 3. FISH characterisation of diagnostic CML and PTCL samples using the commercial probes that 
recognise the BCR/ABL fusion or the TCRA/D split. (A) Ideogram and a typical example of the pattern 
observed in pathological nuclei hybridised with the Vysis LSI BCR/ABL DC/DF probe showing one fusion, 
two green and one red signals corresponding to the loss of the reciprocal ABL locus. (B) Ideogram and a 
typical example of the pattern seen in lymphoma cells the bear the t(X;14) detected as split in the TCRA/D 
locus. A normal cell with intact 14q locus as testified by the vicinity of the red and green signals and an 
abnormal cell in which one of the two red/green pairs is separated due to the 14q break are shown. (C) 
Experiments performed combining the two probes. Big red signal corresponds to the ABL locus, the big 
green one to the BCR locus, whist the little red and green hybridisation spots correspond to the TCRA/D 
locus. Ideograms and examples of hybridisation are shown as well as an ideogram of an inexistent cell 
bearing both translocations.
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with Taq polymerase obtained from New England Biolabs (Ipswich, MA, USA). qPCR was done utilis-
ing the SybrGreen (Applied Biosystems, Foster City, CA, USA) technology on the 7500 Fast Real-Time 
PCR System (Applied Biosystems) machine. Vysis LSI BCR/ABL Dual Color/Dual Fusion probe (Abbott 
Molecular Inc., Des Plaines, IL, USA) and TCRA/D Locus Break-apart probe (Cytocell, Cambridge, 
UK) were used according to manufactures’ instructions on methanol/acetic acid-fixed material previ-
ously used for conventional cytogenetic analysis. For infrequent cells (< 10%) a total of 1000 cells were 
scored, whilst for frequent ones the scoring stopped at 200 nuclei. Slides hybridised with single probes 
were scored on the Olympus BX51 microscope (Olympus Corporation, Tokyo, Japan) equipped with 
the UPlanSApo 100X/1.40 oil, ∞/0.17/FN26.5 and a FITC/Texas Red double-band pass filter (Chroma 
Technology Corp® , Bellows Falls, VT, USA). Slides hybridised with the two probes together were ana-
lysed by capture on the Olympus BX61 fitted with the UPlanApo 100x/1.35 oil Iris, ∞/0.17, separate 
DAPI, FITC and wide-band red fluorescence (U-WMIY2) filters and CoolSNAP EZ CCD Camera 
(Photometrics, Tucson, AZ, USA). The capture was driven by the MetaMorph Microscopy Automation 
and Image Analysis Software (Molecular Devices, LLC, USA). Representative single colour images were 
saved as TIFF files and processed with the ImageJ tool devised by Wayne Rasband (wayne@codon.nih.
gov, Research Services Branch, National Institute of Mental Health, Bethesda, MD, USA).
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